27519886|t|Meta-Analysis of 29 Experiments Evaluating the Effects of Rapamycin on Life Span in the Laboratory Mouse
27519886|a|Rapamycin has favorable effects on aging in mice and may eventually be applied to encourage " healthy aging " in humans. This study analyzed raw data from 29 survival studies of rapamycin - and control - treated mice, with the goals of estimating summary statistics and identifying factors associated with effect size heterogeneity. Meta-analysis demonstrated significant heterogeneity across studies, with hazard ratio (HR) estimates ranging from 0.22 (95% confidence interval [CI]: 0.06-0.82) to 0.92 (95% CI: 0.65-1.28). Sex was the major factor accounting for effect size variation, and mortality was decreased more in females (HR = 0.41; 95% CI: 0.35-0.48) as compared with males (HR = 0.63; 95% CI: 0.55-0.71). Rapamycin effects were also genotype dependent, however, with stronger survivorship increases in hybrid mice (14.4%; 95% CI: 12.5-16.3%) relative to pure inbred strains (8.8%; 95% CI: 6.2-11.6%). Number needed to treat was applied as an effect size metric, which consistently identified early senescence as the age of peak treatment benefit. These results provide synthesis of existing data to support the potential translation of findings from mouse to primate species. Because rapamycin's effect on survival depends on sex and genotype, further work is justified to understand how these factors shape treatment response.
27519886	0	13	Meta-Analysis	T062	C0920317
27519886	20	31	Experiments	T062	C0681814
27519886	32	42	Evaluating	T058	C1261322
27519886	47	57	Effects of	T080	C1704420
27519886	58	67	Rapamycin	T109,T195	C0072980
27519886	71	80	Life Span	T102	C0870809
27519886	88	104	Laboratory Mouse	T015	C0025929
27519886	105	114	Rapamycin	T109,T195	C0072980
27519886	129	136	effects	T080	C1280500
27519886	140	145	aging	T040	C0001811
27519886	149	153	mice	T015	C0025929
27519886	176	183	applied	T169	C4048755
27519886	199	206	healthy	T080	C3898900
27519886	207	212	aging	T040	C0001811
27519886	218	224	humans	T016	C0086418
27519886	231	236	study	T062	C2603343
27519886	237	245	analyzed	T062	C0936012
27519886	246	249	raw	T080	C1709843
27519886	250	254	data	T078	C1511726
27519886	263	279	survival studies	T062	C0038953
27519886	283	292	rapamycin	T109,T195	C0072980
27519886	299	306	control	T167	C1550141
27519886	309	316	treated	T169	C1522326
27519886	317	321	mice	T015	C0025929
27519886	332	337	goals	T170	C0018017
27519886	341	351	estimating	T081	C0750572
27519886	352	359	summary	T170	C1706244
27519886	360	370	statistics	T170	C0600673
27519886	375	386	identifying	T080	C0205396
27519886	387	394	factors	T169	C1521761
27519886	395	410	associated with	T080	C0332281
27519886	411	422	effect size	T081	C0814843
27519886	423	436	heterogeneity	T080	C0019409
27519886	438	451	Meta-analysis	T062	C0920317
27519886	452	464	demonstrated	T080	C0443289
27519886	465	476	significant	T078	C0750502
27519886	477	490	heterogeneity	T080	C0019409
27519886	498	505	studies	T059	C0947630
27519886	512	524	hazard ratio	T081	C2985465
27519886	525	529	(HR)	T081	C2985465
27519886	530	539	estimates	T081	C0750572
27519886	540	547	ranging	T081	C1514721
27519886	563	582	confidence interval	T081	C0009667
27519886	583	587	[CI]	T081	C0009667
27519886	613	615	CI	T081	C0009667
27519886	629	632	Sex	T032	C1522384
27519886	641	646	major	T080	C0205164
27519886	647	653	factor	T169	C1521761
27519886	654	664	accounting	T169	C0586014
27519886	669	680	effect size	T081	C0814843
27519886	681	690	variation	T080	C0205419
27519886	696	705	mortality	T081	C0205848
27519886	710	719	decreased	T081	C0205216
27519886	720	724	more	T081	C0205172
27519886	728	735	females	T032	C0086287
27519886	737	739	HR	T081	C2985465
27519886	752	754	CI	T081	C0009667
27519886	770	778	compared	T052	C1707455
27519886	784	789	males	T032	C0086582
27519886	791	793	HR	T081	C2985465
27519886	806	808	CI	T081	C0009667
27519886	822	831	Rapamycin	T109,T195	C0072980
27519886	832	839	effects	T080	C1280500
27519886	850	858	genotype	T032	C0017431
27519886	859	868	dependent	T080	C1701901
27519886	884	892	stronger	T080	C0442821
27519886	893	905	survivorship	T079	C0038955
27519886	906	915	increases	T169	C0442805
27519886	919	925	hybrid	T001	C0020205
27519886	926	930	mice	T015	C0025929
27519886	943	945	CI	T081	C0009667
27519886	959	967	relative	T080	C0205345
27519886	971	975	pure	T001	C0599804
27519886	976	990	inbred strains	T015	C0025927
27519886	1002	1004	CI	T081	C0009667
27519886	1018	1024	Number	T081	C0237753
27519886	1025	1031	needed	T169	C1514873
27519886	1035	1040	treat	T169	C1522326
27519886	1045	1052	applied	T169	C4048755
27519886	1059	1070	effect size	T081	C0814843
27519886	1071	1077	metric	T081	C0025867
27519886	1098	1108	identified	T080	C0205396
27519886	1115	1125	senescence	T033	C0231337
27519886	1133	1136	age	T032	C0001779
27519886	1140	1144	peak	T080	C0444505
27519886	1145	1154	treatment	T169	C0039798
27519886	1155	1162	benefit	T081	C0814225
27519886	1170	1177	results	T169	C1274040
27519886	1178	1185	provide	T052	C1999230
27519886	1186	1195	synthesis	T052	C1883254
27519886	1199	1207	existing	T077	C2987476
27519886	1208	1212	data	T078	C1511726
27519886	1216	1223	support	T077	C1521721
27519886	1238	1249	translation	T062	C3494164
27519886	1253	1261	findings	T033	C0243095
27519886	1267	1272	mouse	T015	C0025929
27519886	1276	1291	primate species	T015	C0033147
27519886	1301	1312	rapamycin's	T109,T195	C0072980
27519886	1313	1319	effect	T080	C1280500
27519886	1323	1331	survival	T052	C0038952
27519886	1332	1339	depends	T080	C1701901
27519886	1343	1346	sex	T032	C1522384
27519886	1351	1359	genotype	T032	C0017431
27519886	1411	1418	factors	T169	C1521761
27519886	1425	1434	treatment	T169	C0039798
27519886	1435	1443	response	T032	C0871261